Development of bioactive probes and anti-cancer agents

Project: Research project

Project Details

Description

This project has discovered and developed a novel chemotype for the potential treatment of cancer. The studies underway have elucidated some of the key chemical structure necessary for the observed activity and further studies are underway to fully delineate the structure activity relationships of this class of molecules. The development of these molecules is underway to advance from the initial hit into a lead structure for treatment development. Additionally the core has facilitated the preparation of other biological probes for the study biologically relevant processes. Projects collaboratively supported by the core facility include: Z01 DK036136-02 -- The deubiquitinating inhibitor EerI induces tumor cell apoptosis Z01 AR041099-17 -- Genetic Metabolic Myopathies--phosphofructokinase/acid Maltase Deficiency Z01 AR041165-01 -- Role of Skeletal Muscle SIRT1 in the Pathogenesis of Metabolic Disorders Z01 DK031119-04 -- Chemically Modified Peptide Nucleic Acids
StatusFinished
Effective start/end date3/1/066/30/12

Funding

  • National Institutes of Health: $281,668.00
  • National Institutes of Health: $394,250.00
  • National Institutes of Health: $281,668.00
  • National Institutes of Health: $296,000.00
  • National Institutes of Health: $287,416.00

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.